Synbio International, Inc. (OTC: SYIN) today announced its transition into commercial operations through the introduction of its Healing Force™ nutraceutical division. The company is launching Healing Force™ Anxiety Relief, a natural wellness product designed to address everyday stress and anxiety without pharmaceutical intervention.
“This marks Synbio’s transition into an operating company,” said CEO Claudio Solitario, describing the launch as the start of a strategy to build sustainable shareholder returns through diversified revenue channels.
The global nutraceuticals sector is projected to expand significantly, growing from approximately $684 billion currently to over $1.1 trillion by 2033, driven by consumer preference for preventative health approaches and natural products.
Go-to-Market Strategy
The company plans to distribute Healing Force™ products through direct-to-consumer online channels paired with targeted digital marketing. This capital-efficient approach is intended to allow rapid scaling while maintaining financial flexibility for future product introductions.
Dr. David Anderson, who guided product development, emphasized the company’s commitment to evidence-based wellness solutions that address consumer demand for natural stress management approaches.
A Dual-Track Strategy
Synbio continues to advance its AI-driven facial analysis platform for mental health screening through the FacialDx initiative, pursuing a dual-track strategy that combines near-term commercial opportunities in nutraceuticals with long-term technology development in AI-based diagnostics.
This release may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding Synbio International Inc.’s business strategy, product development, clinical trial plans, and future operations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and readers should not place undue reliance on them. Synbio undertakes no obligation to update any forward-looking statement except as required by law.
For informational purposes only — this release is republished from the company’s official disclosures and public news distribution. Investors should refer to Synbio International’s filings on the Investors page and on OTC Markets for complete and current information.